• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·064550.KQ
Share

Bioneer Corporation Stocks

₩ 6840Last Updated 07.08.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

₩ 112.38M

₩ 6840
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Bioneer Corporation, established in 1992 and headquartered in Daejeon, South Korea, is a biotechnology company involved in diverse fields such as research products, molecular diagnostics, pharmaceuticals, and probiotics. For the biotechnology research market, Bioneer offers a wide array of consumables and reagents, including PCR and RT-PCR kits, real-time PCR solutions, RNA interference products, various chemicals, plastic laboratory essentials, and buffer solutions. The company also provides an extensive range of services like sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher services, electrophoresis, genome-wide functional analysis, and magnetic separation techniques. Additionally, Bioneer manufactures sophisticated instruments for conventional and real-time PCR, sample preparation, protein synthesis, centrifugation, vortex mixing, electrophoresis, spectrophotometry, and microbial culture. In molecular diagnostics, it supplies MDx technologies, human diagnostic kits, MDx extraction kits, and the necessary instrumentation. Furthermore, Bioneer develops specialized products for animal health and cutting-edge nano-biotechnology applications.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is underpriced on P/E, of fair value on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

08.08.2026 19:49

Berkshire Hathaway has reduced its "cash cushion" for the first time in four years

08.08.2026 16:01

Small-Cap Highlights: SolarEdge Forecast, Bitdeer's $4.7 Billion Deal, Replimune's Success

08.08.2026 13:01

A Hot Topic from SpaceX, Burry’s Bleak Outlook, and a Touching “Startup” Born Out of Necessity

08.08.2026 12:15

Ukraine has promised the U.S. not to attack the CPC infrastructure in the Black Sea — Bloomberg

08.08.2026 03:20

Billionaire Ekman Identified the Main Risk for Investors in the Anthropic and OpenAI IPOs

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026